Skip to main content
. 2022 Nov 16;16(12):21417–21430. doi: 10.1021/acsnano.2c09788

Figure 2.

Figure 2

Pharmacokinetics and biodistribution of OxPt/SN38. PK profiles of IRI or Chol-SN38 from OxPt/SN38 (a), SN38 from IRI or SN38-TMS and SN38 from OxPt/SN38 (b), and Pt (c) in rat plasma after an i.v. injection of OxPt plus IRI or OxPt/SN38 at doses of 2.0 mg/kg OxPt and 3.6 mg/kg SN38 equiv. Time-dependent accumulation of SN38 prodrugs (d, g), SN38 (e, h), and Pt (f, i) after an i.v. injection of OxPt plus IRI or OxPt/SN38 at 3.5 mg/kg OxPt and 6.2 mg/kg SN38 equiv) to MC38 tumor-bearing mice.